DHA-conjugated phosphatidylserine

Phosphatidylserine (PS) is a major phospholipid in brain cell membranes and is important for membrane fluidity, signaling, and neurotransmitter release. DHA is a major structural omega-3 in brain phospholipids, particularly important for synapse function. By combining the two, manufacturers aim to deliver both molecules together for incorporation into brain membranes. After ingestion, phospholipids are partially digested in the gut, with fatty acids and head groups recombining in absorbing cells. Whether DHA-PS produces clinical benefits beyond taking DHA and PS separately is not clearly demonstrated.

Typical phosphatidylserine doses in studies are 100-300 mg/day, with DHA-PS products providing similar PS amounts plus a small amount of DHA (often 30-80 mg). The DHA RDA-equivalent is not formally set, but adequate intake of long-chain omega-3s is generally considered 250-500 mg combined EPA+DHA per day.

Most products are taken with food to improve absorption of the fatty acid component. Some users split into two doses.

Phosphatidylserine and DHA are generally well tolerated. Mild GI symptoms (nausea, bloating) are the most common reported side effects. Older bovine-brain-derived PS carried theoretical concerns and is no longer used; modern PS is soy- or sunflower-derived.

DHA may have mild antiplatelet effects, with theoretical additive risk when combined with anticoagulants. PS has been suggested to potentiate cholinesterase inhibitors in older studies, but interaction data are limited.